Efavirenz (EFV) Concentrations in Pregnant Women Taking EFV-Based Antiretroviral Therapy (ART) with ...
This presentation is the property of its rightful owner.
Sponsored Links
1 / 16

Background PowerPoint PPT Presentation


  • 82 Views
  • Uploaded on
  • Presentation posted in: General

Efavirenz (EFV) Concentrations in Pregnant Women Taking EFV-Based Antiretroviral Therapy (ART) with and without Rifampin-Containing Tuberculosis (TB) Treatment.

Download Presentation

Background

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Background

Efavirenz (EFV) Concentrations in Pregnant Women Taking EFV-Based Antiretroviral Therapy (ART) with and without Rifampin-Containing Tuberculosis (TB) Treatment

Helen McIlleron, Neil Martinson, Paolo Denti, FildahMashabela,Jennifer Hunt, Saba Shembe, Jennifer Hull, David W. Haas, Regina Msandiwa, Silvia Cohn, Sandra Meredith, LubbeWiesner, Richard Chaisson, Kelly E. Dooley, and the TSHEPISO Study Team


Background

Background

  • In South Africa, the current standard of care for pregnant women with HIV infection and < 350 CD4 cells/mm3is combination ART

  • There are limited data on efavirenz (EFV) pharmacokinetics (PK) in pregnant women, though its use is increasing (Cresseyet al., 2012)

  • In Soweto, an estimated 0.8-2.2% of pregnant women with HIV also have active TB (Gounder et al. 2011; Kali et al. 2006)

  • Rifampin, a key component of first-line TB treatment, reduces concentrations of many antiretroviral (ARV) drugs

  • The combined effect of pregnancy and rifampin-containing TB treatment on EFV PK, virologic suppression and prevention of maternal-to-child transmission of HIV-1 (PMTCT) has not been studied


Study design

Study design

  • TSHEPISO is a prospective cohort study among HIV-infected pregnant women with TB (n=250 CASES) and without TB (n=500 CONTROLS), currently enrolling in Soweto, South Africa

  • Antenatal clinics and obstetrics ward at Chris Hani Baragwanath Hospital, women at 13-34 weeks gestation

  • Impact of TB/HIV co-infection in pregnancy on maternal and infant outcomes being evaluated

  • Women (n=150) with and without TB, on EFV-containing ART (600 mg QD) will enroll in an EFV PK/PD substudy, along with their infants

  •  We report preliminary results from 76 women and 70 infants in the TSHEPISO EFV PK substudy to date


Methods efv pk substudy

Methods: EFV PK Substudy

  • Blood samples for EFV PK analysis were collected:

    • Maternal: 37 weeks gestation or delivery, then 6 weeks post-partum; up to 4 samples per occasion

    • Cord blood at delivery, infant sample at 7 days

  • Plasma concentrations determined by LCMS/MS†

  • CYP2B6 genotyping of maternal DNA§

    • Extensive = 516GG and 983TT

    • Intermediate = 516GT or 983CT

    • Slow = 516TT or (516GT and 983CT) or 983CC

    • Very Slow = 983CC

  • Post-hoc Bayesian estimates of PK parameters from NLME modeling with allometric scaling, using NONMEM

  • HIV-1 viral load collected at delivery for mothers, at 6 weeks for infants

†Clinical Pharmacology Analytical Laboratory, University of Cape Town; §Pharmacogenomics Laboratory, Vanderbilt University, Nashville and University of the Witwatersrand, Johannesburg


Results study participants

Results: Study participants

*p<0.05 in univariate analysis


Efv population pk model

EFV Population PK Model

Central

Compartment

Absorption

Compartment

F=1 (FIXED)

BOV 32.2%

TV Ka=

0.417 h-1

Dose

TV V/F=469 L

TV CL/F, by genotype:

Extensive: 19.7 L/h

Intermediate: 12.1 L/h

Slow: 7.99 L/h

Very Slow: 2.19 L/h

BSV 35.6%

For Slower metabolizers:

CL/F -59%

when on RIF co-treatment

TV CL/F=

11.7 L/h

BSV 65.5%

BOV 33.9%


Efv population pk model features

EFV Population PK model features

  • 1-compartment model

  • Visits excluded if all EFV samples BLQ (13 PK samples in 10 participants)

  • Allometric scaling with body weight applied to CL/F and V/F

  • CL/F strongly influenced by CYP2B6 genotype

  • Did not detect significant longitudinal variations in EFV PK (pre/post partum)

  • Rifampicin co-treatment decreased EFV CL/F in slower metabolizers


Cyp2b6 and efv pk estimates

CYP2B6 and EFV PK estimates

*

*1 Very Slow has EFV value > upper limit of assay


Maternal efv pk estimates by pregnancy status and rifampin co treatment

Maternal EFV PK estimates, by pregnancy status and rifampin co-treatment

The population PK model post-hoc estimates were used to predict individual Cmin,

reported here with the BLQ values that could not be included in the model

*Median (IQR)


Maternal efv pk estimates effect of weight and rif

Maternal EFV PK estimates, effect of weight and RIF

*Median (IQR)


Cord blood and infant pk results

Cord blood and infant PK results

  • Cord blood (n=45)

    • Median EFV concentration 1.15 (0.628 – 1.91) mg/L

    • Below the limit of quantification in 4/45 (8.9%) samples

  • Infant blood (7 days) (n=57)

    • Median EFV concentration BLQ (BLQ - 0.079) mg/L

    • Below the limit of quantification in 35/57 (61.4%) samples

  • Cord and maternal pre-partum concentrations were highly correlated (r=0.93)

  • Infant 7-days blood concentrations were BLQ in most cases, but quantifiable values were related to larger cord blood concentrations.


Virologic outcomes

Virologic outcomes

  • Maternal viral load at delivery

    • 70% of cases and 83% of controls had VL<20 copies/mL at delivery (p=0.24)

    • Of those taking EFV for at least 12 weeks at delivery, 82% of cases and 93% of controls had VL<20 copies/mL (p=0.26)

  • PMTCT

    • No transmission from women taking EFV at delivery


Limitations

Limitations

  • Single site

  • Sparse sampling

  • Not all participants presented for all sampling visits

  • Observational study in complex setting, no DOT-ART

  • Small sample size for subgroup comparisons


Summary

Summary

  • Rich dataset including 76 women, 70 infants, PK and VL data from high burden HIV/TB setting

  • Estimated Cmin among women pre/intrapartum and post-partum were not significantly different

  • In a model that accounts for weight and CYP2B6 genotype, unable to show significant effect of rifampin on EFV PK (except among slow EFV metabolizers)

  • Despite about 30% with Cmin <1 mg/L, VL suppressed in most women taking EFV for 3 months or more at the time of delivery, and no MTCT


Acknowledgements

Acknowledgements

University of Cape Town

Division of Clinical Pharmacology laboratory Marilyn Solomons

Johns Hopkins University

Chris Hoffmann

Vanderbilt University

Danielle Richardson

Paul Leger

Cara Sutcliffe

Funding

NIH/NICHD R01HD064354 (Chaisson)

NIH K23 (Dooley)

NIH/NIAID R01 AI-077505, NCATS UL1 TR-000011 (Haas)

Perinatal HIV Research Unit

LalaMaseko

Joyce Netshivhale

Abram Maubane

Agnes Shilubane

MatabogoLetutu

Glenda Gray

Chris Hani Baragwanath Hospital

Jennifer Hull

Eckhart Buchman

StheVelaphi

Sanjay Lala

KhakhuMathivha

University of the Witwatersrand

Wendy Stevens

Sergio Carmona

A special thanks to all study participants


Thank you

Thank you


  • Login